<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38797051</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-9157</ISSN><JournalIssue CitedMedium="Internet"><Volume>147</Volume><PubDate><Year>2024</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of autoimmunity</Title><ISOAbbreviation>J Autoimmun</ISOAbbreviation></Journal><ArticleTitle>Diverse immunological dysregulation, chronic inflammation, and impaired erythropoiesis in long COVID patients with chronic fatigue syndrome.</ArticleTitle><Pagination><StartPage>103267</StartPage><MedlinePgn>103267</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaut.2024.103267</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0896-8411(24)00101-X</ELocationID><Abstract><AbstractText>A substantial number of patients recovering from acute SARS-CoV-2 infection present serious lingering symptoms, often referred to as long COVID (LC). However, a subset of these patients exhibits the most debilitating symptoms characterized by ongoing myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS). We specifically identified and studied ME/CFS patients from two independent LC cohorts, at least 12 months post the onset of acute disease, and compared them to the recovered group (R). ME/CFS patients had relatively increased neutrophils and monocytes but reduced lymphocytes. Selective T cell exhaustion with reduced na&#xef;ve but increased terminal effector T cells was observed in these patients. LC was associated with elevated levels of plasma pro-inflammatory cytokines, chemokines, Galectin-9 (Gal-9), and artemin (ARTN). A defined threshold of Gal-9 and ARTN concentrations had a strong association with LC. The expansion of immunosuppressive CD71<sup>+</sup> erythroid cells (CECs) was noted. These cells may modulate the immune response and contribute to increased ARTN concentration, which correlated with pain and cognitive impairment. Serology revealed an elevation in a variety of autoantibodies in LC. Intriguingly, we found that the frequency of 2B4<sup>+</sup>CD160<sup>+</sup> and TIM3<sup>+</sup>CD160<sup>+</sup> CD8<sup>+</sup> T cells completely separated LC patients from the R group. Our further analyses using a multiple regression model revealed that the elevated frequency/levels of CD4 terminal effector, ARTN, CEC, Gal-9, CD8 terminal effector, and MCP1 but lower frequency/levels of TGF-&#x3b2; and MAIT cells can distinguish LC from the R group. Our findings provide a new paradigm in the pathogenesis of ME/CFS to identify strategies for its prevention and treatment.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Suguru</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Dentistry, Division of Foundational Sciences, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahbaz</LastName><ForeName>Shima</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Dentistry, Division of Foundational Sciences, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osman</LastName><ForeName>Mohammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Redmond</LastName><ForeName>Desiree</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bozorgmehr</LastName><ForeName>Najmeh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>School of Dentistry, Division of Foundational Sciences, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosychuk</LastName><ForeName>Rhonda J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Infectious Disease, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary Medicine, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sligl</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada; Department of Medicine, Division of Infectious Diseases, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen Tervaert</LastName><ForeName>Jan Willem</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elahi</LastName><ForeName>Shokrollah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Dentistry, Division of Foundational Sciences, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada; Department of Oncology, University of Alberta, Edmonton, T6G 2E1, AB, Canada; Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada; Li Ka Shing Institute of Virology, Faculty of Medicine &amp; Dentistry, University of Alberta, Edmonton, T6G 2E1, AB, Canada. Electronic address: elahi@ualberta.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Autoimmun</MedlineTA><NlmUniqueID>8812164</NlmUniqueID><ISSNLinking>0896-8411</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037161">Galectins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C105032">LGALS9 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004920" MajorTopicYN="Y">Erythropoiesis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D037161" MajorTopicYN="N">Galectins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artemin</Keyword><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">CD71(+) erythroid cells</Keyword><Keyword MajorTopicYN="N">Galectin-9</Keyword><Keyword MajorTopicYN="N">Inflammation and long COVID</Keyword><Keyword MajorTopicYN="N">MAIT cells</Keyword><Keyword MajorTopicYN="N">T cell exhaustion</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>15</Day><Hour>0</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>26</Day><Hour>18</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38797051</ArticleId><ArticleId IdType="doi">10.1016/j.jaut.2024.103267</ArticleId><ArticleId IdType="pii">S0896-8411(24)00101-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>